Informationen:
Fehler:
ID
14157
Beschreibung
IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT02508324
Link
https://clinicaltrials.gov/show/NCT02508324
Stichworte
Versionen (1)
- 01.04.16 01.04.16 -
Hochgeladen am
1. April 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Acute Myeloid Leukemia NCT02508324
Eligibility Acute Myeloid Leukemia NCT02508324
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Acute Myeloid Leukemia NCT02508324
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Age
Item
Patients must be 18 years of age or older
boolean
C0001779 (UMLS CUI [1])
Aml, MDS
Item
Patients with a confirmed diagnosis of aml or mds, according to who classification (excluding acute promyelocytic leukaemia) who have received two or three previous induction/re-induction regimens. one of the (re-)induction regimens could be stem cell transplantation (sct) for achievement of remission. maintenance and consolidation (including sct) may have been given, but are not counted as previous regimens.
boolean
C0023467 (UMLS CUI [1])
C3463824 (UMLS CUI [2])
C3463824 (UMLS CUI [2])
Complete remission
Item
have never attained cr or cri (primary refractory)
boolean
C0677874 (UMLS CUI [1])
Induction Therapy
Item
Patients have failed initial induction therapy, and have attained cr or cri after salvage therapy(ies), and then relapsed within < 6 months
boolean
C1514832 (UMLS CUI [1])
Relapse
Item
Patients have attained cr or cri after initial induction therapy and relapsed within <12 months, and failed to respond to salvage therapy(ies); or have relapsed after the latest cr or cri within < 6 months
boolean
C0035020 (UMLS CUI [1])
Cytarabine
Item
Patients younger than 60 years should have received previous treatment with cytarabine
boolean
C0010711 (UMLS CUI [1])
Ecog performance status
Item
Patients must have ecog performance status (ps) of 0 - 2
boolean
C1520224 (UMLS CUI [1])
Pregnancy test negative
Item
Women of child-bearing potential must have a negative serum or urine pregnancy test within 2 weeks prior to treatment start
boolean
C0427780 (UMLS CUI [1])
Complying with protocol
Item
Patients must be capable of understanding and complying with protocol requirements, and must be able and willing to sign a written informed consent form
boolean
C0525058 (UMLS CUI [1])
C0021430 (UMLS CUI [2])
C0021430 (UMLS CUI [2])
Toxicity due to chemotherapy
Item
Persistent clinically significant toxicities from previous chemotherapy
boolean
C1302255 (UMLS CUI [1])
hiv
Item
Known positive status for human immunodeficiency virus (hiv)
boolean
C0019682 (UMLS CUI [1])
Patient is pregnant
Item
pregnant and nursing patients
boolean
C3242212 (UMLS CUI [1])
Significant Intercurrent Illness
Item
Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, or psychiatric illness/social situations that would limit compliance with study requirements
boolean
C3640977 (UMLS CUI [1])
Impairment of hepatic or renal function
Item
Iimpairment of hepatic or renal function to such an extent that the patient, in the opinion of the investigator, will be exposed to an excessive risk if entered into this clinical study
boolean
C0086565 (UMLS CUI [1])
C0151746 (UMLS CUI [2])
C0151746 (UMLS CUI [2])
Heart Diseases
Item
active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, arrhythmias not controlled by medication, or uncontrolled congestive heart failure. any nyha grade 3 or 4.
boolean
C0018799 (UMLS CUI [1])
Risk for toxicities
Item
Any medical condition which in the opinion of the investigator places the patient at an unacceptably high risk for toxicities
boolean
C0525058 (UMLS CUI [1,1])
C0013221 (UMLS CUI [1,2])
C0013221 (UMLS CUI [1,2])